Glaukos Corporation (GKOS)
Score for how it compares with the broader market is near the top of its range — smart-money score is below the middle, while price trend score is above the middle.
GKOS scores higher than 85% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Glaukos Corporation (GKOS) scores 60 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 1.33× 30-day average
- 52-week range
- 73.16 – 191.62
- Market cap
- $9.66B
- Earnings date
- 28 Oct 2026
- Volume
- 1,196,008
- Avg. volume (30d)
- 901,924
- Open
- 160.06
- Previous close
- 161.29
- Day's range (regular session)
- 159.89 – 166.97
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.73
- P/E (TTM)
- —
- EPS (TTM)
- -3.26
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for GKOS
- 30 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for GKOS. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about GKOS right now
Glaukos Corporation (GKOS) currently scores 60/100 on the Market Census six-factor composite, at the Above average score level. GKOS is +2.73% on the day and +0.72% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for GKOS leans good, with some weak spots. GKOS's strongest factor is strength vs the market at 93/100 — a very strong read on how GKOS has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is insider trades at 24/100 — a well below average read on insider buying and selling. Insider filings for GKOS lean toward selling; on a thinly filed name a few filings can set this reading.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See GKOS in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent GKOS news
Latest headlines that name Glaukos, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs CataractBenzinga
- Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing DealYahoo
- Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative?Yahoo
- Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal DiseasesYahoo
- Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific BiologicBenzinga
We hide 13 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to GKOS’s 60, all within 1 point.
Sorted by closeness to GKOS’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.